GHRP-2: High-Potency GH Secretagogue Explained

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide and one of the most potent GH secretagogues in the peptide pharmacopeia. Like GHRP-6, it acts on the ghrelin receptor (GHSR-1a) to trigger GH release from the pituitary — but GHRP-2 produces a larger GH pulse per microgram and causes less appetite stimulation than its predecessor. It also raises cortisol and prolactin more significantly than ipamorelin, placing it in a middle ground between the appetite-stimulating GHRP-6 and the highly selective ipamorelin.

GHRP-2 vs. GHRP-6 vs. Ipamorelin

Understanding GHRP-2 requires placing it in the context of the GH secretagogue family:

| Secretagogue | GH Potency | Appetite Effect | Cortisol Effect | Prolactin Effect | |---|---|---|---|---| | GHRP-6 | High | Potent | Moderate | Moderate | | GHRP-2 | Highest | Mild-Moderate | Moderate-High | Moderate-High | | Ipamorelin | Moderate | Minimal | Minimal | Minimal |

GHRP-2 produces the largest GH pulses of the three — studies show peak GH values of 40–70 ng/mL after 1 mcg/kg IV in some subjects — but at the cost of more significant cortisol and prolactin elevation. The appetite effect is less than GHRP-6 but not absent.

Mechanism of Action

GHRP-2 binds GHSR-1a with high affinity and acts as a full agonist, triggering maximal receptor activation. Its mechanism parallels GHRP-6 and ghrelin:

GHSR-1a activation on pituitary somatotrophs triggers intracellular calcium release
This triggers exocytosis of GH-containing secretory granules
Simultaneously, hypothalamic GHSR-1a activation inhibits somatostatin release
Adrenal GHSR-1a activation stimulates cortisol and ACTH release (more pronounced with GHRP-2 than GHRP-6)

The cortisol elevation with GHRP-2 is dose-dependent and acutely significant — studies show cortisol rising 50–100% above baseline within 60 minutes of injection. For most users at typical doses, this returns to baseline within 2–3 hours and does not produce clinical hypercortisolism. However, it is a consideration for individuals with HPA axis dysregulation or high baseline cortisol.

Clinical Research

GHRP-2 has been extensively studied in humans:

GH stimulation testing: GHRP-2 alone and combined with GHRH has been evaluated as a diagnostic tool for GH deficiency. The GHRP-2 + GHRH test (combined) is one of the most potent GH stimulation tests available, producing larger GH peaks than any other single pharmacological stimulus.

Critical illness: Studies in critically ill patients showed that GHRP-2 infusion preserved lean mass and improved nitrogen balance compared to placebo — demonstrating its clinical utility beyond fitness applications.

Pediatric GH deficiency: Multiple studies confirmed GHRP-2 as an effective treatment for children with GH deficiency, including a 12-month randomized controlled trial showing catch-up growth comparable to GH injections.

Japan clinical development: GHRP-2 (brand name Pralmorelin) was approved in Japan for diagnostic use in GH deficiency evaluation. This represents the only regulatory approval any GHRP has received.

Dosage Protocol

Standard dosing:

100–200 mcg subcutaneously per injection
1–3 times daily

Saturation: Like all GHRPs, the GH response saturates at approximately 100–150 mcg. Doses above 200 mcg increase cortisol and prolactin without proportional GH gain.

Timing:

Inject on empty stomach
Pre-sleep dose most critical for GH optimization
Can be combined with a GHRH analog (sermorelin or CJC-1295) for synergistic GH release

Combination protocol:

GHRP-2: 100 mcg
Mod GRF 1-29: 100–200 mcg
Inject simultaneously subcutaneously
1–2x daily

Managing Cortisol and Prolactin

To minimize cortisol and prolactin effects:

Phosphatidylserine: 400–800 mg/day has documented cortisol-blunting effects and is commonly stacked with GHRP-2.

Vitamin C: Antioxidant properties may modulate cortisol response.

Dose timing: The cortisol elevation is most problematic when GHRP-2 is injected multiple times during waking hours. Concentrating doses at bedtime and early morning limits daytime cortisol disruption.

Consider ipamorelin instead: For long-term use where cortisol and prolactin elevation is a concern, switching to ipamorelin provides similar or superior long-term outcomes without the hormonal side effects.

Use Cases Where GHRP-2 Shines

Despite the cortisol and prolactin concerns, GHRP-2 has specific advantages:

Maximal GH stimulation: For short-term protocols (4–6 weeks) where maximum GH pulse amplitude is the priority — such as post-surgery recovery or aggressive body recomposition — GHRP-2's higher potency may be advantageous.

Diagnostic testing: GHRP-2 is used medically to test pituitary GH reserve, as it produces a standardized and highly reliable GH stimulus.

Cost considerations: GHRP-2 is often less expensive per mcg than ipamorelin while producing larger GH pulses, making it appealing for cost-conscious users who can tolerate the side effects.

FAQ

Is GHRP-2 safe for long-term use? Long-term safety data beyond 12 months is limited. The primary concern is chronic cortisol elevation — sustained hypercortisolism causes muscle catabolism, fat accumulation, and immune suppression, working against the goals of GH optimization. Most practitioners recommend using GHRP-2 in shorter cycles (8–12 weeks) and switching to ipamorelin for maintenance phases.

Will GHRP-2 cause gynecomastia from prolactin elevation? The prolactin elevation from standard GHRP-2 doses is modest and typically not sufficient to cause gynecomastia in isolation. However, individuals on anabolic steroids or other prolactin-elevating compounds should be cautious, as effects can be additive.

How does GHRP-2 compare to MK-677? MK-677 (ibutamoren) is an oral GHSR-1a agonist with the same mechanism as GHRP-2 but dramatically longer half-life (24 hours). MK-677 produces sustained GH and IGF-1 elevation from a daily oral dose, while GHRP-2 produces discrete injected pulses. MK-677 also causes significantly more water retention and appetite stimulation.

Track your supplements in Optimize.